Lactobacillus paracasei CCFM1367 capable of converting multiple pueraria flavonoids to enhance effects of dispelling effects of alcohol and protecting liver and metaplasm of lactobacillus paracasei CCFM1367

Through the fermentation technology of C. paracetaccium CCFM1367, the efficient transformation of Pueraria flavonoids was solved, and the problem of low conversion of various Pueraria flavonoids in the existing technology was solved, and the significant effect of quenching alcohol and protecting the liver was achieved, enhancing the biological activity and absorption of Pueraria flavonoids were enhanced. .

CN119060872AActive Publication Date: 2024-12-03JIANGNAN UNIV

Patent Information

Application Number
CN202410546073.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-06
Publication Date
2024-12-03
Estimated Expiration
2044-05-06

AI Technical Summary

Technical Problem

The prior art is difficult to effectively transform a variety of Pueraria flavonoids, which leads to the inadequate utilization of their biological activities in the human body and the inability to effectively alleviate alcoholic liver damage.

Method used

A strain of C. paracetaxanthin was screened and identified. This strain was able to efficiently transform Pueraria flavonoids into active substances, and a composition and preparation with the effect of sucking wine and protecting liver were prepared through fermentation technology.

Benefits of technology

C. paracetium CCFM1367 and its prepared epigenetic and synthenol preparations can significantly improve the ability to relieve alcohol and protect the liver, reduce liver damage, enhance liver antioxidant enzyme activity, regulate alcohol metabolism, reduce intestinal permeability, and enhance the absorption of pueraria flavonoids. Reconciliation wine to protect the liver.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060872A_ABST
    Figure CN119060872A_ABST
Patent Text Reader

Abstract

The invention discloses a lactobacillus paracasei CCFM1367 capable of converting various pueraria flavonoids to enhance the effects of dispelling the effects of alcohol and protecting the liver and a metagen of the lactobacillus paracasei CCFM1367, and belongs to the technical field of microorganisms. The lactobacillus paracasei CCFM1367 provided by the invention and the radix puerariae extract fermentation liquor, synbiotic preparation, viable bacteria or metabiotics prepared from the lactobacillus paracasei CCFM1367 have at least one of the following effects: (1) improving liver tissue pathology; (2) the activity of antioxidant enzymes in liver tissues is enhanced; (3) the inflammatory reaction is relieved; (4) the alcohol metabolism enzyme activity is improved, and the alcohol metabolism is enhanced; and (5) up-regulating the expression of the tight connection related protein-1 and the closed protein in the intestine, and repairing the intestinal barrier injury. The lactobacillus paracasei CCFM1367 provided by the invention and the radix puerariae extract fermentation liquor, synbiotics, viable bacteria and metabiotics prepared from the lactobacillus paracasei CCFM1367 provided by the invention can be used for preparing functional foods and / or dietary supplements with the potential of playing a role in dispelling the effects of alcohol and protecting the liver, and have a huge application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a Lactobacillus paracasei CCFM1367 capable of transforming a variety of kudzu root flavonoids to enhance alcohol sobering and liver protecting effects and a postbiotic thereof, belonging to the technical field of microorganisms. Background Art

[0002] With the accelerated pace of life, drinking has been fully integrated into modern social life. More and more people are joining the drinking ranks, and the age is getting younger and younger. The resulting health damage and social problems are becoming increasingly serious and have attracted the attention of many people. Whether it is long-term chronic intake of alcoholic beverages or sudden alcoholism, it will cause harm to the human body, especially the liver, because after alcohol is absorbed by the gastrointestinal tract, a part of it will be initially metabolized by the alcohol dehydrogenase in the gastrointestinal tract, and more than 90% will be absorbed by the gastrointestinal mucosa, enter the blood, and reach the liver through circulation for metabolism. At present, alcoholic fatty liver disease (ALD) is still an issue that affects global health and needs to be controlled and resolved but has not yet been resolved. Exploring effective treatment measures will help improve global health issues.

[0003] Pueraria lobata flavonoids are mainly extracted from leguminous plants such as kudzu or sweet kudzu vines, and mainly contain some isoflavone compounds, such as puerarin, daidzin, genistin, etc. It is reported that pueraria lobata flavonoids have many effects such as lowering blood lipids, blood sugar, scavenging free radicals, anti-oxidation, osteoporosis, and anti-tumor. It can delay gastric emptying, slow down the absorption rate of alcohol, reduce intestinal wall permeability, and reduce alcohol damage to the liver. At the same time, pueraria lobata flavonoids can regulate the activity of enzymes related to ethanol metabolism, and can also inactivate cytochrome CYP2E1, thereby reducing the free radicals produced by ethanol in the catabolism and reducing the damage to liver cells caused by immune stress response. More importantly, pueraria lobata flavonoids can increase the activity of antioxidant enzymes in the body, reduce oxidative stress, and prevent and treat alcoholic liver damage by regulating the Nrf2 / HO-1 signaling pathway. At present, the use of pueraria lobata flavonoids in the prevention and treatment of alcoholic liver damage has been widely recognized.

[0004] However, direct oral administration of flavonoids from Puerariae Radix is ​​difficult to be absorbed by the human body, resulting in the inability to effectively utilize the biologically active substances in flavonoids from Puerariae Radix. The literature "Human gut microbial degradation of flavonoids: Structure-function relationships" points out that puerarin has an inhibitory effect on the degradation of intestinal bacteria and is not easily degraded by intestinal flora, so the role of puerarin cannot be fully reflected. Microbial fermentation can promote the conversion of flavonoids from Puerariae Radix into easily absorbed small molecules, but no microorganisms that can effectively convert a variety of flavonoids from Puerariae Radix have been found. According to literature reports, most strains cannot utilize puerarin, and even if they have the ability to convert puerarin, their conversion rate is very low (≤5%). "Expression and characterization of the human intestinal bacterial enzyme which cleaves the C-glycosidic bond in 3″-oxo-puerarin" reported a human intestinal bacterial strain PUE that can metabolize puerarin into daidzein, but the strain PUE is not an edible strain and cannot be used to prepare oral products. "Bioconversion of soy isoflavones daidzin and daidzein by Bifidobacterium strains" reported a Bifidobacterium that can convert daidzin to produce daidzein. The conversion rate is about 48%-65% / 7d, which is low and difficult to meet industrial applications. At present, no strain has been found that can simultaneously degrade puerarin, daidzin, genistein and other substances in pueraria flavonoids.

[0005] Lacticaseibacillus paracasei is widely found in nature. Due to its probiotic properties and safety, it is often used in food fermentation, animal feed, industrial lactic acid fermentation, and health care industries. The application of Lactobacillus paracasei in food fermentation is mainly to produce lactic acid and other beneficial substances, adjust the pH value of food, inhibit the growth of harmful bacteria, and improve the taste and flavor of food. However, there are no reports that Lactobacillus paracasei can simultaneously utilize multiple kudzu flavonoids and alleviate alcoholic liver damage. Therefore, screening for bioactive natural products from Chinese herbal medicines that can be produced at low cost using microbial cell factories and achieving the synergistic effect of probiotic fermentation of kudzu flavonoid-rich diets will help promote the development of modern biomanufacturing of Chinese herbal medicines. Summary of the invention

[0006] The technical problem to be solved by the present invention is to provide a strain of Lactobacillus paracasei and the application of postbiotics prepared therefrom and transformed kudzu root flavonoids in enhancing the effects of sobering up and protecting the liver.

[0007] The present invention provides a strain of Lactobacillus paracasei CCFM1367 (Lacticaseibacillus paracasei), which was deposited in Guangdong Provincial Microbiological Culture Collection Center on December 6, 2023, with a deposit number of GDMCC No: 63999, and a deposit address of 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0008] In one embodiment, the Lacticaseibacillus paracasei is isolated from healthy human feces and has the following characteristics:

[0009] The Lactobacillus paracasei CCFM1367 is cultured on the MRS medium for 48 hours and has a rod-shaped bacterial morphology, a smooth and neat surface, occasionally an irregular shape, a moist touch, and is white or milky white, occasionally light yellow.

[0010] The Lactobacillus paracasei CCFM1367 is a Gram-positive bacterium, facultative anaerobic, with an optimal growth temperature of 35-40° C. and an optimal growth pH of 6.0-7.0.

[0011] The Lactobacillus paracasei CCFM1367 can efficiently convert a variety of pueraria flavonoids (such as puerarin and daidzein) into active substances (such as daidzein).

[0012] The invention provides a composition, which contains the Lactobacillus paracasei CCFM1367 or a postbiotic prepared from the Lactobacillus paracasei CCFM1367.

[0013] In one embodiment, the postbiotics include fermentation supernatant, bacterial lysate and / or fermentation broth.

[0014] In one embodiment, the postbiotics are obtained by inoculating the above-mentioned Lactobacillus paracasei CCFM1367 into MRS culture medium to obtain a bacterial liquid, and then performing heat treatment and lysis to obtain the postbiotics.

[0015] In one embodiment, the heat treatment is performed at 60-70° C. for 25-35 min.

[0016] In one embodiment, the fermentation supernatant is the supernatant obtained by centrifuging the fermentation broth.

[0017] In one embodiment, the method for preparing bacterial lysate is to homogenize the heat-treated fermentation broth under high pressure and centrifuge to obtain bacterial lysate.

[0018] In one embodiment, the postbiotics can be dried into powder or used directly by various drying methods such as vacuum drying, spray drying, vacuum freeze drying, fluidized bed drying, etc.

[0019] The present invention also provides a synbiotic preparation with alcohol sobering and liver protecting effects and its application, wherein the content of Lactobacillus paracasei CCFM1367 in the synbiotic preparation is not less than 10 6 CFU / mL or 10 6 CFU / g.

[0020] In one embodiment of the present invention, in the combined preparation, the concentration of Pueraria root extract is ≥5 mg / mL.

[0021] The invention also provides a product, wherein the product contains the Lactobacillus paracasei CCFM1367 or the synbiotic preparation.

[0022] In one embodiment of the present invention, the product is food, medicine or health care product.

[0023] In one embodiment of the present invention, the food, medicine or health product; or the food is a dairy product, bean product or fruit and vegetable product produced using a starter containing the Lactobacillus paracasei CCFM1367; or the food is a beverage or snack containing the Lactobacillus paracasei CCFM1367 according to claim 1.

[0024] The invention provides application of the Lacticaseibacillus paracasei CCFM1367 in preparing a product for sobering up and protecting the liver.

[0025] The invention also provides food, health products, medicines or cosmetics containing the postbiotics and synbiotic preparations of Lactobacillus paracasei CCFM1367.

[0026] In one embodiment, the food comprises the above composition and conventional auxiliary materials.

[0027] In one embodiment, the health care product comprises the above composition and conventional auxiliary materials.

[0028] In one embodiment, the drug comprises the above composition, a drug carrier and / or a pharmaceutical excipient.

[0029] In one embodiment, the pharmaceutical excipients include solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculating agents, filter aids and release retardants.

[0030] In one embodiment, the cosmetic comprises the above composition, matrix raw materials and / or conventional auxiliary materials.

[0031] In one embodiment, the matrix raw materials include oil raw materials, wax raw materials, synthetic oil raw materials, powdery raw materials, colloid raw materials, coagulants, and surfactants.

[0032] In one embodiment, the conventional auxiliary materials include one or more of moisturizers, whitening agents, flavoring agents, adhesives, lubricants, preservatives, film agents, antioxidants, emulsifiers, and cosmetic nutritional additives.

[0033] The invention also provides the use of the Lactobacillus paracasei CCFM1367 in preparing a health product having an auxiliary protective effect on chemical liver damage.

[0034] The invention also provides a method for transforming pueraria lobata flavonoids by using Lactobacillus paracasei. The Lactobacillus paracasei CCFM1367 is added into a reaction system containing pueraria lobata flavonoids for fermentation.

[0035] The invention also provides a method for calculating the conversion rate of pueraria flavonoids.

[0036] In one embodiment of the present invention, the method comprises the following steps:

[0037] (1) Streak the above-mentioned Lactobacillus paracasei CCFM1367 on MRS solid medium and incubate the plate upside down at 37°C for 48 hours. Pick a single colony and inoculate it into 5 mL of MRS liquid medium and incubate it at 37°C for 24 hours.

[0038] (2) Add 5% (v / v) of the bacterial solution of Lactobacillus paracasei to the fermentation base material rich in kudzu root extract, and culture at a constant temperature of 37° C. to prepare a fermentation broth.

[0039] (3) The fermentation broth was collected and centrifuged to obtain the supernatant, which was extracted twice with equal proportions of ethyl acetate, concentrated by refrigerated centrifugation, and then re-dissolved in methanol. After filtering through a 0.22 μm microporous filter membrane, the change in the content of kudzu root flavonoids was detected by HPLC.

[0040] In one embodiment of the present invention, in the fermentation base material rich in kudzu root extract in step (2), the concentration of kudzu root extract is 0.5 mg / mL.

[0041] In one embodiment of the present invention, the amount of the bacterial solution of Lactobacillus paracasei CCFM1367 in step (2) is ≥ 1×10 6 CFU / mL or 1×10 6 CFU / g.

[0042] In one embodiment of the present invention, the constant temperature fermentation culture temperature in step (2) is 30-37° C., and the time is 0-120 h.

[0043] Beneficial effects:

[0044] The present invention screens and obtains a strain of Lacticaseibacillus paracasei CCFM1367, which can transform flavonoids in a kudzu root extract. Moreover, the Lacticaseibacillus paracasei CCFM1367 and postbiotics, kudzu root fermentation liquid, synbiotic preparation and live bacteria prepared therefrom have the ability to improve the ability of sobering up and protecting the liver and have a synergistic effect with kudzu root, which is specifically embodied in the following aspects:

[0045] 1. Lactobacillus paracasei CCFM1367 can efficiently utilize flavonoids in Pueraria lobata, with the conversion rate of puerarin being 25.81±3.36% / 48h; the conversion rate of daidzein being 28.86±3.70% / 48h; and the conversion rate of genistin being 91.62±2.71% / 48h; the increment of daidzein in the product being 721.5±189.2% / 48h, and the content of genistein in the product being 1.51±0.24μg / mL.

[0046] 2. Lactobacillus paracasei CCFM1367 has the effect of sobering up and protecting the liver:

[0047] (1) Reduce liver index and excessive secretion of ALT, AST, TC, TG and LDL-C in serum;

[0048] (2) Improve liver tissue pathological damage and reduce liver damage and lipid deposition caused by long-term drinking;

[0049] (3) Enhance the activity of antioxidant enzymes (GSH, SOD, CAT) in liver tissue;

[0050] (4) Reduce MDA levels and alleviate the damage of free radicals and lipid peroxides to liver cells;

[0051] (5) Inhibit CYP2E1-mediated oxidative stress and enhance the oxidative defense system by activating the Nrf2 / HO-1 pathway;

[0052] (6) Regulate alcohol metabolism and increase the activity of liver alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH);

[0053] (7) Inhibit alcohol-induced upregulation of CYP2E1 and CYP1A2 in the liver and activation of the NF-κB pathway;

[0054] (8) Upregulates the expression of tight junction associated protein-1 (ZO-1) and occludin in the intestine, reduces intestinal permeability, and reduces alcohol absorption.

[0055] 3. After the Lactobacillus paracasei CCFM1367 is co-fermented with Pueraria root, the body can absorb the active substances in Pueraria root and enhance the alcohol-resolving and liver-protecting effects of Pueraria root.

[0056] Therefore, Lacticaseibacillus paracasei CCFM1367 and the postbiotics prepared therefrom, Pueraria lobata fermentation liquid, synbiotic preparations and live bacteria have great application prospects in the preparation of alcohol sobering and liver protecting products.

[0057] Biomaterial Deposit

[0058] A strain of Lacticaseibacillus paracasei CCFM1367, taxonomically named Lacticaseibacillus paracasei, was deposited in the Guangdong Provincial Microbiological Culture Collection Center on December 6, 2023, with the deposit number GDMCC No: 63999, and the deposit address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou. BRIEF DESCRIPTION OF THE DRAWINGS

[0059] Figure 1 : The initial transformation metabolic pathway of pueraria flavonoids.

[0060] Figure 2 : HPLC results of Lactobacillus paracasei CCFM1367 before and after fermentation.

[0061] Figure 3 : Changes of flavonoids content in Puerariae Radix before and after fermentation by Lactobacillus paracasei CCFM1367.

[0062] Figure 4: Effects of Lactobacillus paracasei CCFM1367 and its prepared postbiotic and synbiotic preparations on body weight and liver indices in mice exposed to chronic alcohol.

[0063] Figure 5 : Effects of Lactobacillus paracasei CCFM1367 and its prepared postbiotic and synbiotic preparations on liver histopathology in mice with chronic alcohol exposure.

[0064] Figure 6 : Effects of Lactobacillus paracasei CCFM1367 and its prepared postbiotic and synbiotic preparations on liver function in mice with chronic alcohol exposure.

[0065] Figure 7 : Effects of Lactobacillus paracasei CCFM1367 and its prepared postbiotic and synbiotic preparations on liver oxidative stress levels in mice with chronic alcohol exposure.

[0066] Figure 8 :Effects of Lactobacillus paracasei CCFM1367 and its prepared postbiotics and synbiotic preparations on the mRNA expression levels of inflammatory factors in the liver of mice exposed to chronic alcohol.

[0067] Fig. 9 : Effects of Lactobacillus paracasei CCFM1367 and its prepared postbiotic and synbiotic preparations on alcohol metabolism in mice exposed to chronic alcohol.

[0068] Fig.10 : Effects of Lactobacillus paracasei CCFM1367 and its prepared postbiotic and synbiotic preparations on intestinal barrier function in mice with chronic alcohol exposure. DETAILED DESCRIPTION

[0069] Technical terms:

[0070] The "Pueraria lobata flavonoids" in the present invention include puerarin, daidzein and genistin.

[0071] The "utilization rate" or "conversion rate" in the present invention refers to the reduction in the amount of pueraria flavonoids in the substrate before and after the fermentation of the strain, and the calculation formula is: conversion rate = 1-content after fermentation / content before fermentation × 100%.

[0072] The "postbiotic" in the present invention refers to the collection of bacterial liquid after the strain is fermented (without adding Pueraria root to the culture medium), a part of which is centrifuged to obtain the supernatant, that is, the supernatant of the fermentation liquid of the strain, and the other part is collected after high-pressure homogenization and centrifugation to obtain the precipitate, that is, the bacterial lysate. For details, see Example 3 "Preparation of Postbiotics" herein.

[0073] The "combined preparation" in the present invention refers to the kudzu root extract and the live bacteria being fully mixed and then administered to the mice before gavage. That is, the kudzu root extract and the live bacteria are mixed and prepared by mixing them immediately.

[0074] "Alcoholic fatty liver" in the present invention refers to a disease in which fat accumulates in liver cells due to excessive drinking. There are no specific symptoms at first, but inflammation will occur. As the disease progresses, the following symptoms will appear: helplessness, fatigue, fever, nausea, vomiting, etc. If not treated properly, the disease will develop into alcoholic cirrhosis, manifested as ascites, esophageal varicose bleeding and hepatic coma.

[0075] "Treatment" in the present invention refers to preventing, curing, reversing, attenuating, alleviating, minimizing, inhibiting, suppressing and / or stopping one or more clinical symptoms of a disease after the onset of the disease.

[0076] In the present invention, "prevention" refers to avoiding or reducing the risk of disease occurrence through treatment before the disease occurs, making it difficult for the disease to occur or develop.

[0077] The present invention is further described below in conjunction with specific embodiments, but the present invention is not limited by the implementation regulations.

[0078] In the following examples, SPF-grade male C57bl / 6J mice (6 weeks old, 18±2 g) were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.; the herbal kudzu root extract (40% kudzu root flavonoids) involved in the following examples was purchased from Sanyuan Longsheng Biotechnology Co., Ltd.; puerarin (product number: P816259, CAS: 3681-99-0), daidzein (product number: D807006, CAS: 552-66-9), genistin (product number: The phospholipids (product number: G810548, CAS: 529-59-9), daidzein (product number: D807011, CAS: 486-66-8), and genistein (product number: G810424, CAS: 446-72-0) were purchased from Shanghai MacLean Biochemical Technology Co., Ltd.; Lieber-DeCarli liquid control feed (TP4030C) and Lieber-DeCarli liquid model feed (TP4030B) were purchased from Nantong The samples were purchased from Trophi Feed Technology Co., Ltd. and prepared as required; serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglyceride (TG), lactate dehydrogenase (LDH), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), malondialdehyde (MDA), glutathione (GSH), catalase (CAT) and superoxide dismutase (SOD) assay kits were purchased from Nanjing Jiancheng Bioengineering Institute; mouse LPS enzyme-linked immunosorbent assay kit was purchased from Nanjing Senbeijia Biotechnology Co., Ltd.; chloroform, isopropanol, ethanol, TRIzol and DEPC-treated water were purchased from China National Pharmaceutical Reagent Co., Ltd.; grinding beads were purchased from Huzhou Xiongsheng Grinding Co., Ltd.; BCA protein concentration assay kit was purchased from Shanghai Biyuntian Biotechnology Co., Ltd.; reverse transcription kit and real-time fluorescence quantification kit were purchased from Nanjing Novozyme Biotechnology Co., Ltd.; primers were purchased from Shanghai Shengong Biotechnology Co., Ltd.

[0079] The culture medium involved in the following examples is as follows:

[0080] MRS liquid medium (g / L): peptone 10g / L, yeast extract 5g / L, beef extract 10g / L, glucose 20g / L, anhydrous sodium acetate 2g / L, diammonium hydrogen citrate 2g / L, K2HPO4·3H2O 2.6g / L, MgSO4·7H2O 0.58g / L, MnSO4·7H2O 0.25g / L, Tween-80 1g / L, distilled water 1000g / L. Autoclave at 115℃ for 20min.

[0081] MRS solid medium (g / L): peptone 10g / L, yeast extract 5g / L, beef extract 10g / L, glucose 20g / L, anhydrous sodium acetate 2g / L, diammonium hydrogen citrate 2g / L, K2HPO4·3H2O 2.6g / L, MgSO4·7H2O 0.58g / L, MnSO4·7H2O 0.25g / L, Tween-80 1g / L, agar 20g / L, distilled water 1000g / L. Autoclave at 115℃ for 20min.

[0082] Fermentation medium (0.5 g / L): 0.5 g / L Pueraria extract, 5 g / L yeast extract, 5 g / L glucose, 1000 g / L distilled water. Autoclave at 115°C for 20 min.

[0083] Pueraria extract medium (10 g / L): Pueraria extract 10 g / L, yeast extract 5 g / L, glucose 5 g / L, distilled water 1000 g / L. Autoclave at 115°C for 20 min.

[0084] PBS buffer solution ( / L): 8.0 g sodium chloride, 0.2 g potassium chloride, 1.44 g disodium hydrogen phosphate, 0.24 g potassium dihydrogen phosphate, adjust pH to 7.4. Autoclave at 115°C for 20 min.

[0085] Example 1: Screening, identification and preservation of strains

[0086] 1. Screening

[0087] The fecal samples from healthy people were used as samples and diluted 10-fold to 10 -6 Then take 100 μL of each dilution factor of 10 -4 , 10 -5 , 10 -6 The diluted solution was spread on MRS solid culture medium, cultured at 37℃ for 48h, and the colony morphology was observed and recorded; colonies with different morphologies on the MRS solid culture medium were picked for streak separation, and after cultured at 37℃ for 48h, single colonies with different morphologies on the MRS solid culture medium were picked for streak separation again until pure single colonies with consistent morphology were obtained; pure colonies on the MRS solid culture medium were picked and inoculated into 5mL of MRS liquid culture medium, and cultured at 37℃ for 24h; 1mL of bacterial solution was taken into a sterile centrifuge tube, centrifuged at 8000r / min for 3min, then the upper culture medium was discarded and the obtained bacterial mud was freeze-dried.

[0088] 2. Identification

[0089] The isolated strain was subjected to PCR amplification of 16S rDNA, and the PCR product was sent to Suzhou Jinweizhi Biotechnology Co., Ltd. for sequencing. The obtained PCR product was sequenced by a biological company, and the obtained sequence results were searched and compared for similarity in GeneBank using BLAST to obtain the identification results at the strain species level, as shown in SEQ ID NO.1. Finally, a strain of Lactobacillus paracasei was obtained, named Lactobacillus paracasei CCFM1367, taxonomically named Lactobacillus paracasei, which was deposited in Guangdong Provincial Microbial Culture Collection Center on December 6, 2023, with a deposit number of GDMCC No: 63999.

[0090] The primers used for 16S rDNA amplification are as follows:

[0091] 27F (forward): 5′-AGAGTTTGATCCTGGCCTCA-3′;

[0092] 1492R (reverse): 5'-GGTTACCTTGTTACGACTT-3'.

[0093] The 16S rDNA amplification procedure is as follows:

[0094] 94℃5min; repeat 30 cycles in total (94℃30s; 55℃30s; 72℃2min); 72℃10min; 12℃2min.

[0095] 3. Save

[0096] Lacticaseibacillus paracasei CCFM1367 was inoculated into 5 mL MRS liquid culture medium and cultured at 37°C for 24 h; 1 mL of bacterial solution was taken into a sterile centrifuge tube, centrifuged at 8000 r / min for 3 min, the upper culture medium was discarded, and the bacterial sludge was resuspended in 30% glycerol solution and stored at -80°C.

[0097] Example 2: Conversion of Pueraria lobata flavonoids by Lactobacillus paracasei CCFM1367

[0098] The Lactobacillus paracasei CCFM1367 in Example 1 was streaked on an MRS solid culture medium, and the plate was inverted and cultured at 37° C. for 24 to 48 hours; a single colony was picked and inoculated into 5 mL of an MRS liquid culture medium and cultured at 37° C. for 18 to 24 hours; after being fully mixed, the bacterial solution was inoculated into a new MRS liquid culture medium at an inoculum amount of 2% (v / v) and cultured under the same environment, and this step was repeated 3 to 5 times to obtain a seed solution.

[0099] In 5 mL of fermentation medium rich in pueraria flavonoids (0.5 g / L), 5% (v / v) of the seed solution of Lactobacillus paracasei obtained by the above culture was added and fermented at 37°C for 0 to 120 h. The initial inoculation concentration of the bacterial solution was 1.4 × 10 9 CFU / mL.

[0100] The fermentation broth at different time points was centrifuged and the supernatant was collected. An equal volume of ethyl acetate was added for extraction. The upper liquid was collected and concentrated into dry powder in a 45°C refrigerated centrifuge. 200 μL of 100% chromatographic grade methanol was added for reconstitution. The powder was filtered through a 0.22 μm microporous organic filter membrane to obtain the Pueraria flavonoid fermentation product, which was refrigerated and stored at 4°C for testing.

[0101] HPLC detection of flavonoids content in Pueraria root before and after fermentation:

[0102] Chromatographic conditions are as follows: Chromatographic detection system: Waters e2695; Chromatographic column: Atlantis TM T3 (5 μm, 4.6×250 mm); flow rate: 1.0 mL / min; detection wavelength: 280 nm; injection volume: 5 μL; mobile phase: 0.2% acetic acid aqueous solution (A)-100% methanol solution (B); column temperature 35°C. Elution was performed according to the following gradient: 0-20 min, 30%-70% B; 20-21 min, 70%-30% B; 21-25 min, 30% B.

[0103] Weigh approximately 10 mg of puerarin, daidzein, genistin, daidzein and genistein reference substances in a 100 mL volumetric flask, dilute with analytical pure ethanol solution, and extract ultrasonically at 300W 50Hz for 30 minutes. After cooling, add ethanol to make up the missing weight. Accurately pipette the above solution and dilute to 2 ml of solution with a concentration of 10.0 μg / mL, 25.0 μg / mL, 50.0 μg / mL, 75.0 μg / mL, and 100.0 μg / mL. Make a working curve under the mobile phase, obtain the results, and fit the curve.

[0104] It is reported that microorganisms can transform kudzu root flavonoids into a variety of active small molecules through the enzymes they produce. Figure 1 ). The results of HPLC showed that the contents of puerarin and daidzein in the fermentation broth of pueraria flavonoids were significantly reduced. This shows that pueraria flavonoids can be mostly converted under appropriate conditions, and daidzein is one of the main metabolites ( Figure 2 ).

[0105] The reduction (conversion rate) of the substrate pueraria flavonoids and the increase of the product daidzein before and after fermentation by Lactobacillus paracasei CCFM1367 were compared, and the calculation formula was: conversion rate = 1-content after fermentation / content before fermentation × 100%; increase = (content after fermentation-content before fermentation) / content before fermentation × 100%. When fermented for 48 hours, the conversion rate of puerarin in pueraria flavonoids by Lactobacillus paracasei CCFM1367 was 25.81±3.36% / 48h; the conversion rate of daidzein was 28.86±3.70% / 48h; the conversion rate of genistin was 91.62±2.71% / 48h; the increase of daidzein was 721.5±189.2% / 48h; the content of genistein was 1.51±0.24μg / mL (0.5mg / mL pueraria extract) ( Figure 3 ).

[0106] Example 3: Lactobacillus paracasei CCFM1367 and postbiotic and synbiotic preparations prepared therefrom reduce body weight and liver index in mice

[0107] Preparation of Lactobacillus paracasei CCFM1367 fermented kudzu root extract, postbiotics, live bacteria and synbiotic preparations:

[0108] 1. Preparation of fermented / unfermented Pueraria extract

[0109] Lactobacillus paracasei CCFM1367 was stored in a -80°C refrigerator with 30% glycerol before activation. A small amount of Lactobacillus paracasei CCFM1367 bacterial solution was streaked on an MRS solid culture medium with a sterile inoculation loop, and inverted aerobically cultured at 37°C for 24 to 48 hours; a single colony was picked and inoculated into an MRS liquid culture medium, cultured at 37°C for 18 to 24 hours, and after thorough mixing, the bacterial solution was inoculated into a new MRS liquid culture medium at an inoculation rate of 2% (v / v) and cultured under the same environment. This step was repeated 3 to 5 times to obtain a seed solution. The prepared seed solution was inoculated into a Pueraria extract culture medium (10 g / L) at an inoculation rate of 5% (v / v), and continued to be cultured at 37°C for 48 hours to obtain a fermentation solution, and the number of viable bacteria in the fermentation solution was 2.6×10 8 CFU / mL. The fermentation broth was heat treated at 65°C for 30 min, centrifuged (8000g, 4°C, 15 min), and the supernatant was collected. After freeze-drying, the lyophilized powder (F-PLE) of the fermentation broth of Lactobacillus paracasei CCFM1367 was obtained for use. Unfermented Pueraria extract (UF-PLE), i.e., without inoculation of strains, was prepared in the same manner as above.

[0110] 2. Preparation of postbiotics

[0111] Lactobacillus paracasei CCFM1367 was stored in a -80°C refrigerator with 30% glycerol before activation. A small amount of Lactobacillus paracasei CCFM1367 bacterial solution was streaked on MRS solid medium with a sterile inoculation loop, and inverted aerobically cultured at 37°C for 24 to 48 hours; a single colony was picked and inoculated into MRS liquid medium, cultured at 37°C for 18 to 24 hours, and after thorough mixing, the bacterial solution was inoculated into a new MRS liquid medium at an inoculum volume of 2% (v / v) and cultured under the same environment. This step was repeated 3 to 5 times to obtain 3.5×10 8 CFU / mL of bacterial solution.

[0112] The bacterial solution was heat treated at 65°C for 30 min, centrifuged (8000 g, 4°C, 15 min), the supernatant was collected, and freeze-dried to obtain Lactobacillus paracasei CCFM1367 supernatant freeze-dried powder (CCFM1367-S) for standby use. Another bacterial solution was heat treated, and then high-pressure homogenized (800-1200 MPa, 3 times) to obtain bacterial lysate, and freeze-dried to obtain Lactobacillus paracasei CCFM1367 bacterial lysate freeze-dried powder (CCFM1367-L) for standby use.

[0113] 3. Preparation of live bacteria / synbiotic preparations

[0114] (1) Preparation of live bacteria of Lactobacillus paracasei CCFM1367

[0115] Dip an appropriate amount of bacterial liquid of Lactobacillus paracasei CCFM1367 and streak it, and incubate it aerobically at 37°C for 24 to 48 hours; pick a single colony to MRS liquid culture medium, culture it at 37°C for 18 to 24 hours, mix it thoroughly, and then take the bacterial liquid and inoculate it into a new MRS liquid culture medium at an inoculum volume of 2% (v / v) and culture it under the same environment, repeat this step 3 to 5 times to obtain seed liquid; inoculate the prepared seed liquid into MRS culture medium at an inoculum volume of 2% (v / v) and culture it for 18 to 36 hours, collect the bacterial mud by centrifugation, rinse it thoroughly with phosphate buffer for 3 to 5 times, and resuspend it to 10 10 CFU / mL, and finally freeze-dried to obtain live bacteria freeze-dried powder of Lactobacillus paracasei CCFM1367 (CCFM1367-H). The content of Lactobacillus paracasei CCFM1367 in the bacterial powder is not less than 10 9 CFU / g or 10 10 CFU / g.

[0116] The freeze-dried protective agent ingredients include 100 g / L skim milk powder, 30 mL / L glycerol, 100 g / L maltodextrin, and 150 g / L trehalose. These freeze-dried protective agent raw materials are mixed with purified water to fully dissolve and sterilized at 115° C. for 20 minutes.

[0117] (2) Preparation of synbiotic preparations

[0118] The powder of Lactobacillus paracasei CCFM1367 and the kudzu root extract in step (1) are mixed and dissolved in water to obtain a combined preparation (CCFM1367+PLE), wherein the kudzu root extract content in the combined preparation is not less than 5 mg / mL, and the kudzu root extract content and the number of viable bacteria in the combined preparation are adjusted according to the intragastric dose.

[0119] Establishment of Alcoholic Liver Disease (ALD) Mouse Model:

[0120] The mouse model of alcoholic liver injury was established according to the method described in the literature with slight modifications. First, all mice were subjected to a 7-day liquid diet adaptation period, during which they were fed with Lieber-DeCarli liquid control diet. After the liquid diet adaptation was completed, all mice were randomly divided into 9 groups, namely, blank control group (Control), alcohol model group (Model), positive control group (Positive), unfermented kudzu root extract group (UF-PLE), Lactobacillus paracasei CCFM1367 fermented kudzu root extract group (F-PLE), Lactobacillus paracasei CCFM1367 compound kudzu root extract group (CCFM1367+PLE), live bacteria group (CCFM1367-H), bacterial supernatant group (CCFM1367-S), and bacterial lysate group (CCFM1367-L), with 6 mice in each group. The blank control group continued to be fed with Lieber-DeCarli liquid control diet, and the mice in the other groups were fed with Lieber-DeCarli alcohol liquid model diet for 8 weeks. During the feeding period of the 2nd to 8th week, mice were gavaged every day before 5 pm (the daily gavage dose was calculated based on the weight of the mice). The mice were observed for 30 minutes after each gavage. After the last gavage, all mice were fasted but not watered for 12 hours, weighed, anesthetized, eyeballs were removed to collect blood, and mice were killed by cervical dislocation to collect mouse serum and tissue samples. The experimental animal groups and dosing are shown in Table 1.

[0121] Table 1 Experimental animal groups and drug administration

[0122]

[0123] During the ALD membrane formation period, the mental state of the mice was observed regularly every day, and the weight of the mice was recorded. During the dissection, the complete liver tissue was sampled and washed with phosphate buffered saline (PBS), and the wet weight was measured after drying on filter paper. The mouse liver index = liver weight / mouse weight. Figure 4As shown in the figure, compared with the blank control group (Control), the body weight of mice in the alcohol model group (Model) was significantly reduced, and the liver index was significantly increased (P<0.001). Compared with the Model, the liver index of mice in the fermented Pueraria extract group (F-PLE), the combined preparation group (CCFM1367+PLE), the live bacteria group (CCFM1367-H) and the bacterial supernatant (CCFM1367-S) was significantly reduced (P<0.001), indicating that F-PLE, CCFM1367+PLE, CCFM1367-H and CCFM1367-S prepared by Lactobacillus paracasei CCFM1367 can effectively inhibit the liver swelling of mice caused by chronic alcohol exposure.

[0124] Depend on Figure 4 B shows that the unfermented kudzu root extract group (UF-PLE) had no significant effect on the body weight of mice (24.34±0.62g, equivalent to 23.92±0.29g in the model group), while the fermented kudzu root extract group (F-PLE) could significantly reduce the body weight of mice (24.10±0.11g) and restore it to a level equivalent to that of the control group. Figure 4 C shows that the unfermented kudzu root extract group (UF-PLE) had no effect on the liver index of mice (4.99±0.17%, equivalent to 4.90±0.09% in the model group), while the fermented kudzu root extract group (F-PLE) could significantly reduce the liver index of mice (4.34±0.10%). Compared with the model group, the liver index of F-PLE decreased by 11.54%. The above results show that after fermentation of Lactobacillus paracasei CCFM1367 and kudzu root extract, it will further inhibit the liver swelling of mice caused by chronic alcohol exposure, achieving a synergistic effect.

[0125] Example 4: Lactobacillus paracasei CCFM1367 and its postbiotic and synbiotic preparations alleviate alcohol-induced liver pathological changes in mice

[0126] The specific experimental settings refer to Example 3. After the liver tissue was fixed in 4% paraformaldehyde solution for 24 h, hematoxylin-eosin (H&E) staining was performed to evaluate the degree of liver fatty degeneration and inflammation. Frozen sections of fresh liver tissue embedded in OCT were cut and stained with Oil Red O to observe the accumulation of lipids in the liver. The stained tissue sections were observed under an optical microscope. The section results are shown in Figure 5As shown in the figure, the liver tissue structure of mice in the Control group was normal, without obvious fat droplet vacuoles and fatty degeneration. The liver of mice in the Model group showed severe fatty degeneration and lipid droplet accumulation, and many round vacuoles of different sizes were seen in the cytoplasm, indicating that the chronic ALD model of up to 7 weeks was successfully established. Compared with the Model group, the liver lobules and hepatocyte cord structures of mice in the F-PLE group, CCFM1367+PLE group and CCFM1367-H group were basically normal, and the fatty degeneration was significantly alleviated. A small amount of fat droplet particles and inflammatory cell infiltration were observed in the tissue, and the hepatocyte edema was lower than that in the Model group. It shows that F-PLE, CCFM1367+PLE and CCFM1367-H prepared by Lactobacillus paracasei CCFM1367 can effectively alleviate the liver pathological changes of mice caused by alcohol, and the above groups have better repair effects on alcohol-induced liver damage compared with the unfermented Pueraria extract group (UF-PLE), bacterial lysate group (CCFM1367-L) and bacterial supernatant group (CCFM1367-S).

[0127] Example 5: Lactobacillus paracasei CCFM1367 and its postbiotic and synbiotic preparations improve alcohol-induced lipid accumulation in mice

[0128] The specific experimental settings refer to Example 3. Serum ALT, AST, TC, TG and LDL-C levels were measured using the corresponding detection kits and according to the instructions. Figure 6 As shown in the results, compared with the Control group, the serum ALT, AST, TC, TG and LDL-C levels of the mice in the Model group were significantly increased (P < 0.001), indicating that long-term alcohol intake caused lipid accumulation in the mice. Compared with the Model group, the serum ALT, AST, TC, TG and LDL-C levels of the mice in the F-PLE group were reduced by 51.83 ± 4.50%, 23.77 ± 4.82%, 28.82 ± 2.75%, 35.47 ± 4.69% and 42.60 ± 6.41%, respectively (P < 0.001). In addition, the lipid accumulation in the mice in the CCFM1367 + PLE, CCFM1367-H and CCFM1367-L groups was also alleviated to varying degrees. The results showed that F-PLE, CCFM1367+PLE and CCFM1367-H prepared by Lactobacillus paracasei CCFM1367 had good lipid-lowering and liver-protecting effects on alcohol-induced liver damage in mice, and significantly reduced the degree of liver damage and fatty lesions.

[0129] Depend on Figure 6D It can be seen that the TG content in the serum of mice in the UF-PLE group (0.52±0.03mmol / L) was close to that in the model group (0.56±0.02mmol / L), while the TG content in the serum of mice in the F-PLE group (0.35±0.06mmol / L) was 38.46% lower than that in the model group, indicating that fermentation of Lactobacillus paracasei CCFM1367 with Pueraria extract can significantly improve the degree of liver damage and fatty lesions in mice, playing a synergistic role.

[0130] Example 6: Lactobacillus paracasei CCFM1367 and its postbiotic and synbiotic preparations improve the level of alcohol-induced oxidative stress in the liver of mice

[0131] Refer to Example 3 for the specific experimental setup. Take part of the frozen liver tissue and weigh it, add PBS (pH 7.4, 4°C) at a ratio of 1:9 (m / V), homogenize, centrifuge at 4°C, 12,000×g for 30 min, collect the supernatant, and measure the levels of MDA, GSH, SOD and CAT according to the instructions of the corresponding kit. Use an animal RNA extraction kit to extract total RNA from mouse liver tissue, and then use a reverse transcription kit to reverse transcribe the extracted RNA into cDNA. Using cDNA as a template, real-time fluorescence quantitative PCR was performed using a fluorescent dye embedding method, and mouse GAPDH was used as an internal reference gene. -ΔΔCt The mRNA expression levels of target genes COX-2, Nrf2, HO-1 and Gclc were calculated by the method. The target genes in each group were expressed as their expression levels relative to the blank control group (set to 1.0). The primers were synthesized by Shanghai Sangon Biotechnology Co., Ltd., and the primer sequences are shown in Table 2.

[0132] Table 2 Real-time fluorescence quantitative PCR detection primer sequences

[0133]

[0134] The results are as follows Figure 7As shown in the figure, compared with the Control group, the activities of GSH, SOD and CAT in the liver of the Model group mice were significantly reduced (P < 0.001), indicating that the liver of the Model group mice had oxidative damage. Consistent with the intervention effect of bifendate in the Positive group, the alcohol-induced GSH depletion and the decrease of SOD and CAT activities were significantly improved after the intervention of F-PLE, CCFM1367+PLE and CCFM1367-H (P < 0.001). Among them, after the intervention of F-PLE prepared by fermentation of Pueraria extract by Lactobacillus paracasei CCFM1367, the GSH content and SOD and CAT levels in the liver of mice increased by 195.6 ± 18.72%, 190.4 ± 16.15% and 122.7 ± 4.37%, respectively (P < 0.001). In addition, the liver GSH content (16.30±0.70μmol / gprot) and SOD (189.34±7.76U / mgprot) and CAT (26.71±0.48U / mgprot) activities of mice in the F-PLE group were higher than those in the UF-PLE intervention group (GSH content and SOD and CAT activities were 8.38±0.66μmol / gprot, 101.60±10.23U / mgprot and 21.79±0.54U / mgprot, respectively). The MDA content in the liver of the mice in the Model group was the highest. Compared with the Model group, the MDA content in the liver of the mice in the F-PLE group was reduced by 49.42±2.19% (P<0.001), and the MDA content in the liver of the mice in the UF-PLE group, CCFM1367+PLE group, CCFM1367-H group, and CCFM1367-L group was also reduced to varying degrees (P<0.001). This indicates that the antioxidant capacity of the liver tissue of the mice in the F-PLE group, CCFM1367+PLE group, CCFM1367-H group, and CCFM1367-L group has been improved.

[0135] In addition, compared with the Control group, the expression of COX-2 gene in liver tissue of mice in the Model group was significantly increased (P<0.001), and the expression of Nrf2, HO-1 and Gclc genes was significantly decreased (P<0.001). Compared with the Model, the expression level of COX-2 gene in liver tissue of mice in the Positive group and F-PLE group was significantly decreased, and the expression level of Nrf2, HO-1 and Gclc genes was significantly increased (P<0.001). Among them, the relative expression level of COX-2 gene in liver tissue of mice in F-PLE group (1.81±0.49) decreased by 66.10±8.56% (P<0.001), and the relative expression levels of Nrf2, HO-1 and Gclc genes (0.91±0.12, 1.11±0.26, 0.89±0.14) increased by 314.0±31.43%, 191.9±22.88% and 165.69±19.92%, respectively (P<0.001), and the expression of each gene recovered to the level equivalent to that of the control group. The expression level of COX-2 gene in the liver tissue of mice in the UF-PLE group (3.23±0.96) was 39.86% lower than that in the Model group, and the expression levels of Nrf2, HO-1 and Gclc genes (0.51±0.19, 0.66±0.10, 0.62±0.09) increased by 174.81%, 114.28% and 115.23%, respectively, which could not reach the same level as that in the control group. The above results show that the F-PLE intervention prepared by fermenting Pueraria extract with Lactobacillus paracasei CCFM1367 effectively inhibited the increase of oxidative stress level in the liver of mice induced by long-term alcohol exposure, and compared with the unfermented Pueraria extract, the F-PLE prepared by fermenting Lactobacillus paracasei CCFM1367 with Pueraria extract can further improve the effect of inhibiting the oxidative stress level in mice.

[0136] Example 7: Lactobacillus paracasei CCFM1367 and its postbiotic and synbiotic preparations alleviate alcohol-induced liver inflammation and damage in mice

[0137] The specific experimental settings refer to Example 3. Take part of the frozen liver tissue and weigh it, add PBS (pH 7.4, 4°C) at 1:9 (m / V), homogenize, centrifuge at 4°C, 12,000×g for 30 min, collect the supernatant, and detect the LPS level in the liver according to the relevant operating instructions of the ELISA kit. The mRNA expression levels of TNF-α, IL-10, IL-6 and IL-1β in mouse liver tissue were detected by qRT-PCR, and the primer sequences are shown in Table 3.

[0138] Table 3 Real-time fluorescence quantitative PCR detection primer sequences

[0139]

[0140]

[0141] The results are as follows Figure 8 As shown in the figure, compared with the Control group, the mRNA expression levels of inflammatory factors TNF-α, IL-10, IL-6 and IL-1β in the liver tissue of mice in the Model group were significantly increased (P < 0.001), indicating that long-term ethanol intake induced an inflammatory response in the liver. However, consistent with the trend of the Positive group, the mRNA expression levels of proinflammatory factors TNF-α, IL-10, IL-6 and IL-1β in the liver tissue of alcohol-treated mice were improved to varying degrees after intervention with F-PLE, CCFM1367+PLE and CCFM1367-H. Among them, compared with the model group, the mRNA expression levels of proinflammatory factors TNF-α, IL-10, and IL-6 in the liver tissue of mice after CCFM1367+PLE intervention were reduced by 84.68±5.51%, 84.24±3.76% and 80.63±1.83%, respectively; after CCFM1367-H intervention, the mRNA expression levels of proinflammatory factors TNF-α, IL-10, and IL-6 in the liver tissue of mice were reduced by 76.36±3.07%, 78.31±6.84% and 91.52±1.54%, respectively; but neither of them could effectively reduce the mRNA expression level of IL-1β. After F-PLE intervention, the mRNA expression levels of pro-inflammatory factors TNF-α, IL-10, IL-6 and IL-1β in the liver tissue of mice were effectively regulated, decreasing by 89.62±2.84%, 86.93±3.03%, 97.24±0.44% and 63.22±9.03% (P<0.001), respectively. This indicates that F-PLE prepared by fermentation of Pueraria extract by Lactobacillus paracasei CCFM1367 can significantly inhibit the expression level of inflammatory factors in liver cells induced by alcohol.

[0142] In addition, compared with the model group, the mRNA expression levels of proinflammatory factors TNF-α, IL-10 and IL-6 in the liver tissue of mice after UF-PLE intervention decreased by 87.95±4.41%, 60.77±6.73% and 47.78±3.19%, respectively, and there was no significant difference in the mRNA expression level of IL-1β (P>0.05). The above results show that compared with the oral administration of UF-PLE treatment group, the F-PLE treatment group can enhance the effect of Pueraria lobata flavonoids and has a better repair effect on alcohol-induced liver inflammation and damage.

[0143] Example 8: Lactobacillus paracasei CCFM1367 and postbiotic and synbiotic preparations prepared therefrom regulate the alcohol metabolism ability of mice

[0144] Refer to Example 3 for the specific experimental setup. The metabolism of ethanol mainly occurs in the liver, and ethanol is metabolized into carbon dioxide and water and excreted from the body through several different metabolic pathways. The cytochrome P450 enzyme system includes many types, of which CYP4502E1 is only one of the subclasses, and CYP2E1 is a metabolic enzyme subfamily metabolic pathway with obvious polymorphism. Other metabolic pathways also include alcohol dehydrogenase (ADH), acetaldehyde dehydrogenase (ALDH), etc. Therefore, it is of great significance to assess the degree of liver damage by detecting the activity and expression level of enzymes related to alcohol metabolism in liver tissue. The mRNA expression levels of Cyp2e1 and CYP1A2 in mouse liver tissue were detected by qRT-PCR, and the primer sequences are shown in Table 4.

[0145] Table 4 Real-time fluorescence quantitative PCR detection primer sequences

[0146]

[0147]

[0148] The results are as follows Fig. 9 As shown, compared with the Control group, the activities of ADH and ALDH in the liver tissue of mice in the Model group were significantly decreased (P < 0.001), and the expression levels of Cyp2e1 and CYP1A2 genes were significantly increased (P < 0.001). Compared with the Model, the activities of ADH and ALDH in the liver tissue of the mice in the CCFM1367-PLE group were increased by 248.35±2.78% and 129.61±1.60%, respectively; the activities of ADH and ALDH in the liver tissue of the mice in the CCFM1367-H group were increased by 239.69±8.49% and 116.48±4.94%, respectively; the expression levels of Cyp2e1 and CYP1A2 genes in the liver tissue of the mice in the CCFM1367-PLE group were decreased by 52.16±11.88% and 35.89±9.24%, respectively; the expression levels of Cyp2e1 and CYP1A2 genes in the liver tissue of the mice in the CCFM1367-H group were decreased by 38.48±2.07% and 36.48±6.94%, respectively, returning to the level close to that of the control group. The above results showed that the combined preparation group (CCFM1367-PLE) and the live bacteria group (CCFM1367-H) could effectively regulate the ADH and ALDH activities, and the Cyp2e1 and CYP1A2 gene expression levels.

[0149] In addition, co-fermentation of Lactobacillus paracasei CCFM1367 and Pueraria extract (F-PLE) can enhance the alcohol-detoxifying and liver-protecting effects of Pueraria extract on mice. Compared with the Model, the activities of ADH and ALDH in the liver tissue of mice in the F-PLE group increased by 213.89±13.39% and 122.72±6.17% (P<0.001), respectively, and the expression levels of Cyp2e1 and CYP1A2 genes decreased by 74.97±12.87% and 50.02±5.80% (P<0.001), respectively. Although the UF-PLE group also had a certain regulatory effect on the activities of ADH and ALDH and the expression levels of Cyp2e1 and CYP1A2 genes, the effect was not as good as that of the F-PLE group. The ALDH activity of the UF-PLE group was only 83.61% of that of the F-PLE group, the Cyp2e1 expression level was 1.93 times that of the F-PLE group, and the CYP1A2 expression level was 1.54 times that of the F-PLE group, reflecting the synergistic promotion effect of Lactobacillus paracasei CCFM1367 and Pueraria extract after fermentation. The above results show that the protective effect of F-PLE prepared by fermentation of Pueraria extract with Lactobacillus paracasei CCFM1367 on mice induced by long-term alcohol exposure includes: regulating the activity of alcohol metabolism enzymes, promoting ADH and ALDH activities, inhibiting the activity of Cyp2e1 and CYP1A2 and downregulating gene expression, thereby reducing the damage of alcohol metabolites to the liver, indicating that Lactobacillus paracasei CCFM1367 and Pueraria extract play a synergistic role in alcohol sobering up and protecting the liver.

[0150] Example 9: Lactobacillus paracasei CCFM1367 and postbiotic and synbiotic preparations prepared therefrom improve alcohol-induced impairment of intestinal barrier function in mice

[0151] Please refer to Example 3 for the specific experimental settings. It has been reported that alcohol and its metabolites can damage the intestinal barrier function, causing excessive enteric endotoxin LPS to enter the blood and liver, thereby activating liver immune cells and triggering a series of inflammatory responses, ultimately leading to liver damage. According to the aforementioned studies, fermented kudzu root extract (F-PLE) and Lactobacillus paracasei CCFM1367 powder mixed with kudzu root extract to obtain a synbiotic preparation (CCFM1367+PLE) can significantly improve liver fatty degeneration and lipid accumulation caused by long-term alcohol exposure, and reduce the damage of free radicals and lipid peroxides to liver cells. Therefore, it is necessary to continue to pay attention to the effects of these two groups on the intestinal barrier function of mice. The expression levels of ileal tight junction proteins ZO-1 and Occludin in the Control group, Model group, Positive group, F-PLE group and CCFM1367+PLE group of mice were detected by immunofluorescence staining ( Fig.10) The observation results showed that the fluorescence intensity of ileum tight junction protein in the Positive group (the average fluorescence intensity of ZO-1 and Occludin were 43.30±2.69 and 57.44±4.00, respectively), F-PLE group (the average fluorescence intensity of ZO-1 and Occludin were 42.49±2.40 and 50.26±2.99, respectively) and CCFM1367+PLE group (the average fluorescence intensity of ZO-1 and Occludin were 42.22±2.42 and 56.22±2.72, respectively) was significantly higher than that in the Mode group (the average fluorescence intensity of ZO-1 and Occludin were 38.11±1.48 and 44.61±2.67, respectively), indicating that the expression levels of intestinal barrier-related functional proteins in the mice intervention groups of bifendate, fermented Pueraria extract and synergistic preparation were increased, and the function of the intestinal barrier was improved.

[0152] Comparative Example 1

[0153] With reference to Example 2, the difference is that Lactobacillus paracasei CCFM1120 is used instead of Lactobacillus paracasei CCFM1367. The result shows that, by calculating the reduction (conversion rate) of substrate kudzu flavonoids and the increment of product daidzein before and after fermentation of Lactobacillus paracasei CCFM1120, it is found that during fermentation for 48h, the conversion rate of puerarin in kudzu flavonoids by Lactobacillus paracasei CCFM1120 is 6.86% / 48h; the conversion rate of daidzein is 48.52% / 48h; the conversion rate of genistin is 14.81% / 48h; and the increment of product daidzein is 206.69% / 48h. The conversion rate of puerarin in pueraria flavonoids by Lactobacillus paracasei CCFM1367 was 25.81% / 48h; the conversion rate of daidzein was 28.86 / 48h; the conversion rate of genistin was 91.62% / 48h; the increase of daidzein in the product was 721.5% / 48h. In general, in terms of degradation and utilization of pueraria flavonoids, Lactobacillus paracasei CCFM1367 has a higher conversion rate, can better promote the release of active ingredients, and improve the pharmacological activity of pueraria flavonoids.

[0154] Comparative Example 2

[0155] The specific embodiment of the invention is with reference to Example 3, difference is, replace lactobacillus paracasei CCFM1367 with lactobacillus paracasei CCFM1120, result shows, compared to model group (activity of ALT is 36.78U / L), the activity of ALT in lactobacillus paracasei CCFM1120 viable bacteria group mouse serum is 27.50U / L, and ALT activity reduces by 25.23%.And after lactobacillus paracasei CCFM1367 viable bacteria intervenes, compared to model group (activity of ALT is 25.18U / L), ALT activity is 10.14U / L in mouse serum, and ALT activity reduces by 59.73%.In addition, after lactobacillus paracasei CCFM1367 viable bacteria intervenes, compared to model group, TC, TG and LDL-C content reduce by 26.93%, 22.63% and 38.57% respectively in mouse serum. Therefore, in terms of lipid-lowering and liver-protecting effects, the intervention effect of the live bacteria group of Lactobacillus paracasei CCFM1367 was better.

[0156] Compared with the model group (MDA concentration was 5.51nmol / mg protein, SOD and GSH concentrations were 75.33U / mg protein and 4.60μmol / g protein), the MDA concentration in the liver of mice in the Lactobacillus paracasei CCFM1120 group was significantly reduced (3.53nmol / mg protein), and the SOD and GSH activities were significantly increased (118.01U / mg protein and 7.19μmol / g protein). The MDA concentration was reduced by 35.93%, and the SOD and GSH activities were increased by 156.67% and 156.30%, respectively. After the intervention of live bacteria of Lactobacillus paracasei CCFM1367, the MDA content in the liver of mice was reduced by 52.43%, and the SOD and GSH activities were increased by 154.79% and 167.68%, respectively, compared with the model group. In addition, after the intervention of live bacteria of Lactobacillus paracasei CCFM1367, the CAT content in the liver of mice was increased by 129.97% compared with the model group. Therefore, the live bacteria group of Lactobacillus paracasei CCFM1367 is more effective in alleviating alcohol-induced liver oxidative damage.

[0157] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.

Claims

1. A strain of Lactobacillus paracasei CCFM1367, characterized in that: The Lactobacillus paracasei CCFM1367 was deposited in the Guangdong Provincial Microbiological Culture Collection Center on December 6, 2023, with the deposit number GDMCC No: 63999.

2. A composition comprising Lactobacillus paracasei CCFM1367 according to claim 1.

3. The composition according to claim 2, characterized in that The composition contains the Lactobacillus paracasei CCFM1367 strain, or contains postbiotics prepared by the Lactobacillus paracasei CCFM1367.

4. The composition according to claim 3, characterized in that The Lactobacillus paracasei CCFM1367 strain includes a live strain, a dry strain or an inactivated Lactobacillus paracasei CCFM1367.

5. The composition according to claim 3, characterized in that The postbiotics include one or more substances in the metabolites of Lactobacillus paracasei CCFM1367, the fermentation broth of Lactobacillus paracasei CCFM1367, the lysate of Lactobacillus paracasei CCFM1367 or the extract of Lactobacillus paracasei CCFM1367.

6. A product containing the composition according to any one of claims 2 to 5.

7. The product according to claim 6, characterized in that In the product, the content of Lactobacillus paracasei CCFM1367 is not less than 10 6 CFU / mL or 10 6 CFU / g.

8. The product according to claim 6 or 7, characterized in that The product also contains kudzu root extract, and the content of the kudzu root extract is ≥5 mg / mL.

9. The product according to any one of claims 6 to 8, characterized in that: The product is food, medicine, health care product or cosmetics.

10. The product according to claim 9, characterized in that The food is a fermented food; the fermented food includes dairy products, bean products or fruit and vegetable products, or the food is a beverage or snack containing the Lactobacillus paracasei CCFM1367 according to claim 1.

11. The product according to claim 9, characterized in that The drug comprises a drug carrier and / or a pharmaceutical excipient; the pharmaceutical excipient comprises a solvent, a propellant, a solubilizer, a cosolvent, an emulsifier, a colorant, an adhesive, a disintegrant, a filler, a lubricant, a wetting agent, an osmotic pressure regulator, a stabilizer, a glidant, a flavoring agent, a preservative, a suspending agent, a coating material, a fragrance, an anti-adhesive agent, an integrator, a penetration enhancer, a pH regulator, a buffer, a plasticizer, a surfactant, a foaming agent, a defoaming agent, a thickener, a inclusion agent, a humectant, an absorbent, a diluent, a flocculant and a deflocculating agent, a filter aid and a release retardant.

12. Use of the Lactobacillus paracasei CCFM1367 of claim 1 or the composition of any one of claims 2 to 5 in the preparation of a product that promotes the decomposition of kudzu flavonoids.

13. Use of the Lactobacillus paracasei CCFM1367 of claim 1, or the composition of any one of claims 2 to 5, or the product of any one of claims 6 to 11 in the preparation of a drug for sobering up and protecting the liver.

14. Use of the Lactobacillus paracasei CCFM1367 of claim 1, or the composition of any one of claims 2 to 5, or the product of any one of claims 6 to 11 in the preparation of a health product having an auxiliary protective effect on chemical liver damage.

15. A method for transforming kudzu root flavonoids using Lactobacillus paracasei, characterized in that: The Lactobacillus paracasei CCFM1367 of claim 1 is added to a reaction system containing kudzu flavonoids for fermentation.

Citation Information

Patent Citations

  • Hangover alleviating and liver protecting functional fermented beverage and preparation method thereof

    CN111406856A

  • Lactobacillus paracasei capable of relieving alcoholic intestinal injury and application of lactobacillus paracasei capable of relieving alcoholic intestinal injury

    CN111662850A

  • Preparation and application of lactobacillus viable bacteria and pueraria flavone combined capsule

    CN117338833A

  • Anti-osteoporosis agent

    JP2009114112A

Cited By

  • Lactobacillus paracasei and malt extract composition for synergistically improving functional constipation

    CN119823922A

  • Probiotic composition for relieving acute drunkenness as well as preparation method and application thereof

    CN120210079A

  • A probiotic composition for alleviating acute drunkenness, and its preparation method and application

    CN120210079B

  • Lactobacillus paracasei for degrading acetaldehyde and application of lactobacillus paracasei

    CN121674271A